Abstract | AIMS: METHODS: RESULTS: After propensity matching (n = 1321 in each group), ticagrelor was associated with lower incidence of MACCEs compared with clopidogrel (3.9 vs. 5.9%, hazard ratio [HR] = 0.65, 95% confidence interval [CI] 0.45-0.92, p = .015). The incidence of TIMI bleeding events was higher in the ticagrelor group than in the clopidogrel group (4.5 vs. 2.9%, HR = 1.90, 95% CI 1.25-2.88, p = .024). The difference between ticagrelor and clopidogrel for net adverse clinical events was nonsignificant (4.3 vs. 4.9%, HR = 0.88, 95% CI 0.61-1.27, p = .458). CONCLUSIONS:
Ticagrelor was associated with a lower incidence of MACCEs and an increased risk of TIMI bleeding events in East Asian patients with CAD receiving PCI.
|
Authors | Jianan Li, Hong Qiu, Lirong Yan, Tingting Guo, Yong Wang, Yang Li, Jianfeng Zheng, Yida Tang, Bo Xu, Shubin Qiao, Yuejin Yang, Runlin Gao |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 36
Issue 11
Pg. 1739-1745
(11 2020)
ISSN: 1473-4877 [Electronic] England |
PMID | 32945695
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Clopidogrel
- Ticagrelor
|
Topics |
- Aged
- Asian People
- Clopidogrel
(adverse effects, therapeutic use)
- Coronary Artery Disease
(drug therapy, mortality, surgery)
- Female
- Hemorrhage
(etiology, prevention & control)
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(etiology)
- Percutaneous Coronary Intervention
(adverse effects, methods)
- Platelet Aggregation Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Preoperative Care
- Ticagrelor
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|